New Launch14 Jul 2025, 04:52 pm
Sun Pharma Announces Launch of LEQSELVI™ in the US for Severe Alopecia Areata Treatment
AI Summary
Sun Pharmaceutical Industries Limited has announced the launch of LEQSELVI™ (deuruxolitinib) 8 mg tablets in the United States. LEQSELVI is indicated for the treatment of adults with severe alopecia areata. The launch represents a key milestone for Sun Pharma and an important advancement for the alopecia areata community, as there are limited treatment options available for people living with severe alopecia areata in the U.S.
Key Highlights
- LEQSELVI is now available for prescription in the U.S. for the treatment of severe alopecia areata
- Demonstrated rapid results in clinical trials with one third of patients regaining almost all of their hair by Week 24
- The psychosocial impact of alopecia areata can be significant, and LEQSELVI provides clinicians with an important new treatment that can deliver significant, rapid outcomes for patients with alopecia areata
- LEQSELVI may cause serious side effects including serious infections, malignancies, thrombosis, gastrointestinal perforations, and certain laboratory abnormalities
- Sun Pharma is committed to making LEQSELVI accessible to patients through the LEQSELVI SUPPORT™ Program